ES2101012T3 - Derivados de acidos guanidinoalquilo-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion. - Google Patents

Derivados de acidos guanidinoalquilo-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.

Info

Publication number
ES2101012T3
ES2101012T3 ES92121077T ES92121077T ES2101012T3 ES 2101012 T3 ES2101012 T3 ES 2101012T3 ES 92121077 T ES92121077 T ES 92121077T ES 92121077 T ES92121077 T ES 92121077T ES 2101012 T3 ES2101012 T3 ES 2101012T3
Authority
ES
Spain
Prior art keywords
procedure
guanidinoalkyl
derivatives
preparation
atomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92121077T
Other languages
English (en)
Inventor
Hans-Jochen Dr Lang
Christoph Dr Naumann
Denis Carniato
Anne-Marie Moura
Ryochi Satoh
Masakazu Katoh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2101012T3 publication Critical patent/ES2101012T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025—Esters of poly(thio)phosphonic acids
    • C07F9/405—Esters of poly(thio)phosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA INVENCION DESCRIBE COMPUESTOS TAUTOMEROS DE LAS FORMULA IA, IB O IC Y/O SUS SALES FISIOLOGICAMENTE TOLERABLES, EN LAS QUE R1, R2, R3, R4, R5, R6 O R7 SON ATOMOS DE HIDROGENO, (C1 C7) STITUIDO, (C1 C4) UIDO, R2 Y R3, R3 Y R4 Y R5 FORMAN UN ANILLO SATURADO, MONOCICLICO DE 5 A 7 MIEMBROS O INSATURADO HETEROCICLICO, QUE ESTA UNA O VARIAS VECES SUSTITUIDO, R8, R9, R10 O R11 SON ATOMOS DE HIDROGENO O (C1 ROXI O HALOGENO, L Y N SON UNA CIFRA ENTERA DE 0 A 2, LA SUMA DE LAS CIFRAS L, M Y N ES MENOR O IGUAL A 10; PROCEDIMIENTO PARA LA OBTENCION DE LOS COMPUESTOS DE LAS FORMULAS IA, IB O IC, MEDICAMENTOS ASI COMO SU UTILIZACION PARA LA PROFILAXIS O EL TRATAMIENTO DE LA OSTEOPOROSIS.
ES92121077T 1991-12-12 1992-12-10 Derivados de acidos guanidinoalquilo-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion. Expired - Lifetime ES2101012T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4140908 1991-12-12
DE4211976 1992-04-09

Publications (1)

Publication Number Publication Date
ES2101012T3 true ES2101012T3 (es) 1997-07-01

Family

ID=25910001

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92121077T Expired - Lifetime ES2101012T3 (es) 1991-12-12 1992-12-10 Derivados de acidos guanidinoalquilo-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.

Country Status (16)

Country Link
US (1) US5294608A (es)
EP (1) EP0546548B1 (es)
JP (1) JP3377234B2 (es)
KR (1) KR100269544B1 (es)
AT (1) ATE152453T1 (es)
AU (1) AU657018B2 (es)
BR (1) BR9204984A (es)
CA (1) CA2085171C (es)
DE (1) DE59208426D1 (es)
DK (1) DK0546548T3 (es)
ES (1) ES2101012T3 (es)
FI (1) FI105550B (es)
MX (1) MX9207215A (es)
NZ (1) NZ245414A (es)
RU (1) RU2124519C1 (es)
TW (1) TW222637B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4223940A1 (de) * 1992-07-21 1994-01-27 Boehringer Mannheim Gmbh Neue acyclische Amidingruppen-haltige Diphosphonsäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE59309360D1 (de) * 1992-12-02 1999-03-18 Hoechst Ag Guanidinalkyl-1, 1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
JPH06298779A (ja) * 1993-04-15 1994-10-25 Hoechst Japan Ltd ヘテロ環イミノビスメチレンビスホスホン酸誘導体
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
DE19546736A1 (de) * 1995-12-14 1997-06-19 Hoechst Ag Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
ATE253073T1 (de) 1997-03-07 2003-11-15 Metabasis Therapeutics Inc Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase
IT1303672B1 (it) 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
JP2003519183A (ja) * 2000-01-04 2003-06-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心臓および動脈の石灰化を抑制する低用量ビスホスホネートの使用
WO2007109585A2 (en) * 2006-03-17 2007-09-27 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
US7358361B2 (en) * 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US7457149B2 (en) 2006-05-05 2008-11-25 Macronix International Co., Ltd. Methods and apparatus for thermally assisted programming of a magnetic memory device
JP2010523709A (ja) * 2007-04-12 2010-07-15 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ Ｆｐｐｓ、ｇｇｐｐｓ及びｄｐｐｓを含む複数の標的に対して高い効能を有するビスホスホネート化合物及び方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3225469A1 (de) * 1982-07-05 1984-01-05 Schering AG, 1000 Berlin und 4709 Bergkamen Diphosphonsaeure-derivate und diese enthaltende pharmazeutische praeparate
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
ES2039237T3 (es) * 1986-04-24 1993-09-16 Fujisawa Pharmaceutical Co., Ltd. Procedimiento para preparar nuevos compuestos de acido difosfonico.
EP0282309A3 (en) * 1987-03-11 1990-03-14 Yamanouchi Pharmaceutical Co. Ltd. Azole-aminomethylene bisphosphonic acid derivatives
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
US4990503A (en) * 1988-08-12 1991-02-05 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclic bisphosphonic acid derivatives

Also Published As

Publication number Publication date
DE59208426D1 (de) 1997-06-05
AU3017392A (en) 1993-06-17
BR9204984A (pt) 1993-06-15
KR100269544B1 (ko) 2000-10-16
EP0546548A1 (de) 1993-06-16
CA2085171C (en) 2003-12-02
FI925617A0 (fi) 1992-12-10
ATE152453T1 (de) 1997-05-15
FI925617A (fi) 1993-06-13
MX9207215A (es) 1993-06-01
JP3377234B2 (ja) 2003-02-17
EP0546548B1 (de) 1997-05-02
AU657018B2 (en) 1995-02-23
RU2124519C1 (ru) 1999-01-10
NZ245414A (en) 1995-04-27
DK0546548T3 (da) 1997-10-13
TW222637B (es) 1994-04-21
FI105550B (fi) 2000-09-15
JPH05271260A (ja) 1993-10-19
US5294608A (en) 1994-03-15
CA2085171A1 (en) 1993-06-13

Similar Documents

Publication Publication Date Title
ES2101012T3 (es) Derivados de acidos guanidinoalquilo-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.
ES2104708T3 (es) Compuestos heterociclicos terapeuticos.
ES2161290T3 (es) Derivados de quinazolina.
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
ES2054860T3 (es) Nuevos derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion, asi como a su utilizacion como medicamentos.
AR008878A1 (es) Antagonistas del receptor de vitronectina, un metodo para su preparacion, una composicion farmaceutica que los contiene y el uso de las mismas para la preparacion de un medicamento.
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
PA8494101A1 (es) Derivados heterociclicos utiles como agentes anticancerosos
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
AR009052A1 (es) Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen y un procedimiento para obtener estas preparaciones farmaceuticas
PA8431301A1 (es) Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
GT199900150A (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas.
MX9300786A (es) Compuestos hipolipidaemicos.
ECSP066349A (es) Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales
AR013079A1 (es) Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
AR019496A1 (es) Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos
ES2524369T3 (es) Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento
AR015446A1 (es) Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
AR025046A1 (es) Inhibidores il-5 no esteroidales, procedimientos e intermediarios para su preparacion y composiciones farmaceuticas que comprenden dichos inhibidores
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.
MX9401080A (es) Compuestos heteroaromaticos.
ES2095848T3 (es) Nuevos derivados de fosfolipidos y su utilizacion para la preparacion de medicamentos antiviricos.
ES2070002T3 (es) Composiciones terapeuticas a base de derivados de 1,2-ditiol-3-tiona.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 546548

Country of ref document: ES